Peer-Reviewed

The Appropriate Omalizumab Patient

Management of the uncontrolled asthma patient and case examples

Jill Karpel, MD
Beth Thalheim Asthma Center, North Shore University Hospital, Manhasset, N.Y.
Donald A. Bukstein, MD
Family Medicine at University of Wisconsin–Madison
Robert LoNigro, MD
Tufts Health Plan, Boston, Mass.

Abstract

Allergy is a significant component in many asthma patients. Omalizumab is a monoclonal anti–immunoglobulin E antibody for the treatment of allergic asthma. Clinical trials have shown that omalizumab treatment is associated with improved symptom control and reduced inhaled corticosteroid doses, resulting in fewer exacerbations and reduced utilization of resources. Omalizumab therapy may benefit patients who remain uncontrolled or who cannot tolerate standard therapy.

Key words: adult, asthma, immunoglobulin E, monoclonal antibody, prior authorization

Corresponding author:

Jill Karpel, MD
Mailing Address:
410 Lakeville Road, Suite 107
New Hyde Park, N.Y. 11040
Fax: 516 465-5454

UP NEXT

A Conversation With Marc Harrison, MD
By Interview by Peter Wehrwein
A Conversation with J. Kevin Croston, MD, and Craig Samitt, MD
By Interview by Peter Wehrwein
A Conversation with Andy Slavitt
By Interview by Richard Mark Kirkner

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report